Kiromic BioPharma Past Earnings Performance
Past criteria checks 0/6
Kiromic BioPharma's earnings have been declining at an average annual rate of -27.5%, while the Biotechs industry saw earnings growing at 12.7% annually.
Key information
-27.5%
Earnings growth rate
17.2%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | n/a |
Return on equity | n/a |
Net Margin | n/a |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Recent updates
Kiromic Biopharma surges 43% as company to begin lung cancer therapy trial in Q1 next year
Oct 06Dr. Leonardo Mirandola is the new Chief Scientific Officer of Kiromic biopharma
Jul 12Kiromic expands in-house cell therapy manufacturing facility, names new COO
Jun 07Kiromic BioPharma files two IND applications for CAR-T therapy in cancer
Dec 17Kiromic BioPharma reports Q3 results
Nov 30Revenue & Expenses BreakdownBeta
How Kiromic BioPharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 0 | -23 | 11 | 9 |
30 Sep 23 | 0 | -25 | 14 | 8 |
30 Jun 23 | 0 | -32 | 16 | 9 |
31 Mar 23 | 0 | -33 | 18 | 11 |
31 Dec 22 | 0 | -35 | 18 | 13 |
30 Sep 22 | 0 | -39 | 22 | 13 |
30 Jun 22 | 0 | -33 | 19 | 13 |
31 Mar 22 | 0 | -29 | 17 | 11 |
31 Dec 21 | 0 | -26 | 15 | 10 |
30 Sep 21 | 0 | -19 | 0 | 9 |
30 Jun 21 | 0 | -15 | -2 | 7 |
31 Mar 21 | 0 | -22 | 6 | 6 |
31 Dec 20 | 0 | -20 | 5 | 5 |
30 Sep 20 | 0 | -19 | 14 | 4 |
30 Jun 20 | 0 | -17 | 13 | 3 |
31 Mar 20 | 0 | -6 | 3 | 2 |
31 Dec 19 | 0 | -4 | 3 | 1 |
31 Dec 18 | 0 | -4 | 2 | 1 |
Quality Earnings: KRBP is currently unprofitable.
Growing Profit Margin: KRBP is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: KRBP is unprofitable, and losses have increased over the past 5 years at a rate of 27.5% per year.
Accelerating Growth: Unable to compare KRBP's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: KRBP is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: KRBP's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.